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Glomerular tip lesion: A distinct entity within the minimal
change disease/focal segmental glomerulosclerosis spectrum.
Background. The glomerular tip lesion (GTL) is a distinctive
but controversial histopathologic lesion occurring in patients
with idiopathic nephrotic syndrome. The relationship of GTL to
minimal change disease (MCD) and idiopathic focal segmental
glomerulosclerosis (FSGS) has been disputed.
Methods. In order to define the clinical features and natu-
ral history of GTL, we retrospectively reviewed the presenting
clinical features, biopsy findings and outcome of 47 cases. Pre-
senting clinical features of GTL were compared to those of
controls with MCD (N = 61) or idiopathic FSGS (N = 50).
Results. The cohort of GTL consisted of 45 adults and two
children (mean age 47.5 years; range 12 to 79 years), includ-
ing 76.6% Caucasians and 53% males. At presentation, 93.6%
of patients had edema, 89.1% had nephrotic syndrome (mean
urine protein 8.31 g, mean serum albumin 2.27 g/dL, and
mean cholesterol 340.6 mg/dL), and 34.8% had renal insuffi-
ciency. Mean time from onset of renal disease to biopsy was
2.4 months. At biopsy, glomerular segmental lesions included
GTL alone in 26%, GTL and peripheral lesions in 6%, GTL
and indeterminate lesions in 36%, and GTL with peripheral
and indeterminate lesions in 32%. No initial biopsy contained
perihilar sclerosis and most (81%) segmental lesions were cel-
lular. Follow-up data were available in 29 patients, of whom 21
received steroids alone and eight received sequential therapy
with steroids and a cytotoxic agent. At a mean follow-up of
21.5 months, 58.6% of patients achieved complete remission of
nephrotic syndrome, 13.8% had partial remission, and 27.6%
had persistent nephrotic proteinuria. Only one patient pro-
gressed to end-stage renal disease (ESRD). Predictors of non-
remission included severity of proteinuria at presentation and
% peripheral lesions. When compared to controls with MCD
and idiopathic FSGS, GTL more closely resembled MCD with
respect to high incidence of nephrotic syndrome (P < 0.001),
severity of proteinuria (P < 0.05), short duration from onset
to biopsy (P < 0.001), and absence of chronic tubulointerstitial
disease (P < 0.0054).
Conclusion. Within the MCD/FSGS spectrum, GTL is a dis-
tinctive and prognostically favorable clinical-pathologic entity
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whose presenting features and outcome more closely approxi-
mate those of MCD.
The glomerular tip lesion (GTL) is a distinctive
histopathologic lesion occurring in patients with idio-
pathic nephrotic syndrome. As first described by Howie
and Brewer in 1984 [1], GTL is a segmental glomerular
lesion defined by its characteristic location at the origin
of the proximal tubule and exhibiting both intracapillary
and extracapillary alterations. In their elegant studies of
renal biopsies using serial sections [1, 2], these investiga-
tors found a small portion of the glomerular tuft situated
at the tubular pole to be expanded either by endocapil-
lary foam cells with pale vacuolated cytoplasm or acel-
lular hyaline material, usually accompanied by adhesion
between the involved glomerular segment and Bowman’s
capsule or the tubular basement membrane. In serial sec-
tions, these changes involve all or nearly all glomeruli.
The overlying podocytes are typically swollen and hyper-
plastic, containing cytoplasmic vacuoles and protein re-
sorption droplets. Frequently there is confluence of these
enlarged visceral epithelial cells with the adjacent proxi-
mal tubular epithelial cells, which may appear small and
capped or swollen and vacuolated. The remainder of the
tuft is histologically normal but shows extensive efface-
ment of foot processes at the ultrastructural level, resem-
bling the podocyte alterations seen in minimal change
disease (MCD). By immunofluorescence, there may be
segmental positivity for IgM and C3 in the tip region,
similar to the immunofluorescence profile seen in fo-
cal segmental glomerulosclerosis (FSGS). Because these
glomerular changes occur in patients with idiopathic
nephrotic syndrome, the relationship of this segmental
lesion to MCD and idiopathic FSGS has been a source of
controversy.
The natural history of GTL is poorly defined. In re-
peat biopsies from patients with GTL, Howie and Brewer
found persistence of GTL in most patients [1, 2]. How-
ever, in some cases the segmental lesions had evolved to
affect a larger glomerular area, extending from the apex
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to the vascular pole and some repeat biopsies contained
lesions of segmental and global sclerosis, indicating pos-
sible progression to irreversible glomerular scarring [1].
In a subsequent study, Howie et al [3] emphasized that
cases where GTL involved all (or nearly all) glomeruli
that are otherwise histologically unremarkable were usu-
ally steroid-responsive and had long-term preservation
of renal function. In contrast, cases of GTL accompa-
nied by diffuse mesangial hypercellularity, cases with dif-
fuse multiple segmental lesions involving all or nearly
all glomeruli, and cases of focal GTL involving fewer
than 50% of glomeruli per biopsy behaved more like
idiopathic FSGS and frequently did not undergo remis-
sion. However, progression of GTL to FSGS with de-
velopment of end-stage renal disease (ESRD) has been
documented in some patients including at least one pa-
tient with typical GTL on initial biopsy (i.e., diffuse GTL,
without mesangial hypercellularity) [2].
Although first described in biopsies that otherwise re-
semble MCD [1, 2], GTL has since been reported in
biopsies where segmental lesions were not restricted
to the tubular pole [4, 5], akin to idiopathic FSGS.
These conflicting data raise questions about how GTL
should be defined within the MCD/FSGS spectrum
and whether it constitutes a distinct clinical-pathologic
entity or should be considered a morphologic vari-
ant of FSGS. “Glomerular tip changes,” identical to
GTL, may also occur superimposed on diverse glomeru-
lar diseases, including membranous nephropathy [6],
diabetic nephropathy [6], IgA nephropathy [6], chronic
allograft nephropathy [7], postinfectious glomeru-
lonephritis [8], and following pre-eclampsia [9]. Similar
pathologic findings have also been described in some
experimental models of proteinuric renal disease [10,
11], suggesting that GTL might represent a nonspecific
glomerular response to proteinuria. Howie et al [8] have
proposed that acute swelling of the glomerular tuft in dif-
ferent glomerular diseases leads to reversible prolapse of
the peripheral tuft into the tubular lumen. In proteinuric
glomerulopathies, the convergence of protein-rich filtrate
toward the tubular pole may cause physical stress on the
paratubular glomerular segments, leading to accumula-
tion of endocapillary foam cells, swelling and detachment
of podocytes, and subsequent tuft adhesion to Bowman’s
capsule.
We report the clinical-pathologic features, treatment,
and outcome of 47 patients with GTL diagnosed at our
institution. Presenting clinical features were compared to
those of a cohort of MCD and classic idiopathic FSGS.
Our results confirm that GTL falls within the clinical-
pathologic spectrum of MCD/idiopathic FSGS, but more
closely resembles MCD with respect to presenting fea-
tures and prognosis. Our data support the view that GTL
is a distinct clinical-pathologic entity with prognostic
significance.
METHODS
Forty-seven cases of GTL were identified retrospec-
tively from among 10,173 native renal biopsies acces-
sioned in the Renal Pathology Laboratory at Columbia
Presbyterian Medical Center between January 1991 and
March 2003, for a biopsy incidence of 0.46%. GTL was
defined according to the guidelines of a recent consensus
classification [12]. Morphologic inclusion criteria were
the presence of at least one glomerulus containing a seg-
mental lesion involving the tip domain (i.e., the outer
25% of the glomerular tuft next to the origin of the prox-
imal tubule) with either adhesion between the tuft and
Bowman’s capsule at the tubular lumen or neck, or con-
fluence of podocytes with parietal or tubular epithelial
cells at the tubular lumen or neck (Fig. 1A). It was re-
quired that the proximal tubular pole be identified in
the defining glomerulus. The GTL could have cellular
features (endocapillary hypercellularity, including foam
cells) (Fig. 1B) or sclerosing features (increased matrix
and/or hyalinosis) (Fig. 1C). Exclusion criteria included
(1) any glomerulus with collapsing sclerosis and (2) any
case with clinical-pathologic features of another primary
glomerular disease (such as membranous nephropathy,
IgA nephropathy, or diabetic glomerulosclerosis).
Clinical data, laboratory findings at presentation, and
follow-up data were obtained from review of biopsy
referral forms and from follow-up telephone conver-
sations with the submitting nephrologists. For adults
(≥18 years of age), the following clinical definitions
were used: nephrotic range proteinuria (NRP), >3 g/day;
hypoalbuminemia, serum albumin <3.5 g/dL; hyperc-
holesterolemia, serum cholesterol >200 mg/dL; renal in-
sufficiency, serum creatinine >1.2 mg/dL; hematuria, >5
red blood cells per high power field on microscopic ex-
amination of the urinary sediment. Nephrotic syndrome
was defined as NRP, hypoalbuminemia, and peripheral
edema. Hypertension was defined as systolic blood pres-
sure >140 mm Hg or diastolic blood pressure >90 mm
Hg. For the two subjects aged <18 years at initial pre-
sentation, NRP was defined as >40 mg/m2/hour [13];
hypoalbuminemia was defined as <2.5 g/dL [13], renal
insufficiency was defined by a calculated creatinine clear-
ance of less than 90 mL/min [14], and hypertension was
defined as a systolic or diastolic blood pressure > the 90th
percentile based on the child’s gender, age, and height
percentile [15]. An estimate of glomerular filtration rate
(GFR) was calculated using a modified Cockcroft-Gault
formula corrected for gender, age, and serum creatinine.
For outcome analysis, stable renal function was defined as
a change in serum creatinine of ≤20% of the initial value.
Complete remission was defined as 24- hour urine pro-
tein of ≤300 mg/day (or dipstick trace) and stable renal
function at last follow-up. Partial remission was defined
by the presence of a 24-hour urine protein of ≤2 g/day (or
up to 2+ by dipstick), a reduction in proteinuria of at least
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Fig. 1. A representative example of glomerular tip lesion. (A) A small segmental lesion located at the tip domain. The origin of the proximal tubule
is clearly identified. The lesion displays endocapillary foam cells and adhesion to Bowman’s capsule. The overlying podocytes appear capped and
confluent with the adjacent tubular epithelial cells. The vascular pole is identified diametrically opposite the tubular pole (hematoxylin and eosin ×
250). (B) High power view of a cellular tip lesion demonstrates expansion of the glomerular segment located at the tubular pole by endocapillary
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50%, and stable renal function at last follow-up. ESRD
was defined as the time point when renal replacement
therapy was started.
For purposes of comparison, the presenting demo-
graphic and clinical features of the GTL group were
compared to those of a control group of 61 consecutive
adult MCD cases (all >18 years old) diagnosed between
1998 and 2003, and a well-characterized historical control
group of 50 patients with classic idiopathic FSGS biopsied
at our institution [16].
Renal biopsies were processed for light microscopy
(LM), immunofluorescence (IF), and electron mi-
croscopy (EM) according to standard techniques. For
LM, at least 11 glass slides, each containing two to three
tissue sections (3 lm thick), were stained with hema-
toxylin and eosin, periodic acid-Schiff (PAS), Masson’s
trichrome, and Jones methenamine-silver (JMS) stains.
Routine IF was performed on 3 lm thick cryostat sec-
tions using polyclonal fluorescein isothiocyanate (FITC)-
conjugated antibodies to IgG, IgM, IgA, C3, C1q, j, k,
fibrinogen, and albumin (Dako Corporation, Carpente-
ria, CA, USA). EM was performed using a JEOL 100S
electron microscope.
The percentage of globally sclerotic glomeruli and seg-
mental lesions in each biopsy was calculated. Each seg-
mental lesion was categorized based on its location with
respect to the tubular pole and glomerular hilus as either
(1) GTL, a segmental lesion involving the tip domain
(i.e., the peripheral 25% of the glomerular tuft adjacent
to the origin of the proximal tubule, with either adhesion
between the tuft and Bowman’s capsule at the tubular
lumen or neck, or confluence of podocytes with parietal
or tubular epithelial cells at the tubular lumen or neck)
(Fig. 1A); (2) peripheral lesion, a segmental lesion that
was either adjacent to the tubular pole, or distant from
the hilar arteriole, but that did not form a GTL in adja-
cent serial sections; (3) perihilar lesion, a segmental lesion
involving the glomerular vascular pole; or (4) indeter-
minate lesions, a segmental lesion whose relationship to
the vascular pole or the origin of the proximal tubule
hypercellularity, including foam cells. There is confluence of the swollen podocytes with the tubular epithelial cells at this site (periodic acid-Schiff
× 400). (C) An example of sclerosing tip lesion illustrates segmental occlusion of glomerular capillary lumina by increased matrix and hyalinosis.
There is adhesion of the sclerosing segment to Bowman’s capsule at the origin of the proximal tubule (periodic acid-Schiff × 250). (D) A peripheral
lesion is identified by its location opposite the vascular pole. The origin of the proximal tubule is not identified in the plane of section (or in the
serial sections reviewed). The segmental lesion exhibits cellular features, with endocapillary foam cells and adhesion to Bowman’s capsule (periodic
acid-Schiff × 250). (E) An indeterminate lesion is identified by the presence of a segmental lesion that can not be oriented with respect to either
the vascular or tubular poles in the plane of section (or in the serial sections reviewed). The indeterminate lesion shown here has sclerosing features
with inframembranous hyalinosis and adhesion to Bowman’s capsule (periodic acid-Schiff × 250). (F) The initial biopsy of the single patient
who progressed to end-stage renal failure (ESRD) is illustrated. Three of the six glomeruli pictured contain cellular tip lesions (arrows). There
is no evidence of tubular atrophy, intersitial fibrosis, or inflammation. (Jones methenamine silver × 100). (G) High power view of a glomerulus
in (F) illustrates the cellular quality of the segmental lesion. The segment located at the tubular origin prolapses into the tubular lumen. The
overlying podocytes are small and capped. At the point of synechia to Bowman’s capsule, the podocytes become confluent with the adjacent tubular
epithelium. (Jones methenamine silver × 400). (H) Repeat biopsy performed 3 years later from this patient shows progression to severe global and
segmental glomerulosclerosis. There is also severe tubular atrophy and interstitial fibrosis, with moderate arteriosclerosis (Jones methenamine silver
× 100).
could not be determined due to the plane of sectioning.
For proper assignment of each segmental lesion to one
of the above categories, all serial sections of the biopsy
were carefully reexamined and each segmental lesion was
tracked through the serial sections for identification of
the vascular and tubular pole. Next, each segmental le-
sion was subclassified as either (1) cellular (with endo-
capillary hypercellularity, including foam cells) (Fig. 1B)
or (2) sclerosing (with increased matrix and/or hyalinosis)
(Fig. 1C). Podocyte hypertrophy and/or hyperplasia were
permissible in both the cellular and sclerosing lesions.
Mesangial hypercellularity, defined by >3 cells/mesangial
region, was graded semiquantitatively on a scale of 0 to
3+ corresponding to absent, mild, moderate, and severe.
Acute tubular injury was identified by the presence of
tubular simplification, loss of brush border, and enlarged
reparative nuclei with nucleoli. Tubular atrophy, intersti-
tial fibrosis, interstitial edema, interstitial inflammation,
and acute tubular injury were graded semiquantitatively
on a scale of 0 to 3+ based on the % cortical area af-
fected (<1%, 1% to 25%; 26% to 50%; and >50%, re-
spectively). Arteriosclerosis and arteriolosclerosis were
graded 0 to 3+ (absent, mild, moderate, and severe, re-
spectively) based on the degree of luminal narrowing
and vessel wall thickening. The intensity of IF staining
was graded 0 (absent), trace (+/−), or 1 to 3+. The
percentage of foot process effacement was determined
quantitatively by estimation (without using morphome-
tric measurements) based on examination of the ultra-
structure of all nonsclerotic glomerular capillaries in all
fields studied.
Statistical analysis
Statistical analysis was performed using nonparamet-
ric exact statistical methods, including the Fisher ex-
act test (for categorical variables), the Wilcoxon rank
sum test (for continuous variables between two groups),
the Kruskal-Wallis test and the Jonckheere-Terpstra test
(for continuous variables among three or more groups),
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Table 1. Clinical presenting features and demographics of
glomerular tip lesion (GTL)
Age years (range) 47.5 (12–79)
Gender male:female 25:22
Race/ethnicity number (%)
Caucasian 36 (76.6)
African American 6 (12.8)
Hispanic 4 (8.5)
Asian 1 (2.1)
Hypertension number (%) 28/46 (61)
Nephrotic parameters
24-hour urine protein excretion g/day (range) 8.31 (2.4–19.8)
Nephrotic range proteinuria
(>3 g/day) number (%) 41/44 (93.2)
Albumin g/dL (range) 2.27 (1.3–3.8)
Edema number (%) 43/46 (93.6)
Cholesterol mg/dL (range) 340.6 (132–778)
Nephrotic syndrome number (%) 41/46 (89.1)
Creatinine mg/dL mean (range) 1.37 (0.5–5.2)
Creatinine >1.2 mg/dL number (%) 16/46 (34.8)
Hematuria number (%) 23/40 (58)
Mean duration of symptoms months (±SEM) 2.4 ± 0.4
and both simple (univariate) and multiple (multivariate)
linear regression analysis (for comparison of continu-
ous variables), using SPSS 11.5 for Windows (Chicago,
IL, USA) and StatXact 5.0 for Windows (Cambridge,
MA, USA). Statistical significance was assumed at
P < 0.05.
RESULTS
Demographic and presenting clinical features of GTL
The cohort of GTL patients included 25 males and 22
females (Table 1). The mean age at presentation was 47.5
years (range 12 to 79 years), including 45 adults and two
children, aged 12 and 15 respectively. There were 36 Cau-
casian patients (76.6%), six African Americans (12.8%),
four Hispanics (8.5%), and one Asian (2.1%).
Presenting laboratory data were available for 46 GTL
patients, all of whom had heavy proteinuria (Table 1).
In the single remaining patient, detailed clinical data
were not available, although the patient was described
as having nephrotic syndrome. The mean 24-hour uri-
nary protein measured in 44 patients was 8.31 g, (range
2.4 to 19.8 g), including 41 with proteinuria >3g/day and
three with subnephrotic proteinuria (mean 2.6 g/24 hours,
range 2.4 to 2.9 g/24 hours). Two additional subjects had
4+dipstick proteinuria, peripheral edema, and hypoalbu-
minemia (1.5 g/dL and 2.2 g/dL, respectively), consistent
with probable nephrotic syndrome. Forty-three patients
had edema that, in most cases, was described by the re-
ferring nephrologist as abrupt in onset. Serum albumin
data were available for 43 patients (mean serum albumin
2.27 g/dL, range 1.3 to 3.8 g/dL), of whom 42 (97.7%)
had hypoalbuminemia. The single exception was an in-
dividual who had a serum albumin level of 3.8 g/dL and
presented with sudden onset edema with a urinary pro-
tein excretion of 3.4 g/24 hours. Overall, 41/46 patients
(89.1%) fulfilled the three defining criteria for nephrotic
syndrome, and four others had two of the three criteria.
The mean duration of renal symptoms prior to biopsy was
2.4 months (median 1 month, range 0.5 to 12 months).
Among 32 patients with available data, 29 (90.6%) had
hypercholesterolemia at presentation with a mean serum
cholesterol of 340.6 mg/dL (range 132 to 778 mg/dL).
Twenty-three of 40 patients (57.5%) had microhematuria
but none had red blood cell casts. Twenty-eight of 46 sub-
jects (61%) had hypertension that was longstanding in 26
and newly diagnosed in two. At presentation, 30/46 pa-
tients (65.2%) had normal renal function (mean serum
creatinine 0.95 mg/dL, range 0.5 to 1.2 mg/dL) and 16/46
patients (34.8%) had renal insufficiency (mean creatinine
2.14 mg/dL, range 1.3 to 5.2 mg/dL). The latter group in-
cluded eight patients who had recently documented nor-
mal renal function and one subject who had longstanding
mild proteinuria and chronic renal insufficiency. Previous
renal function in the other seven patients was unknown.
Thus, at least 8/46 GTL patients (17.4%) had new onset
renal insufficiency at presentation.
Clinical and serologic findings in GTL patients not
detailed in Table 1 included five with low titer pos-
itive antinuclear antibody but with no other clinical
or laboratory evidence of systemic lupus erythemato-
sus (SLE); two with monoclonal spike on serum elec-
trophoresis, but without clinical or radiological evidence
of multiple myeloma; one with human immunodeficiency
virus (HIV) infection; one with positive hepatitis B sur-
face antigen and positive hepatitis C virus antibody;
one with low titer antineutrophil cytoplasmic antibody
(ANCA); one with anticardiolipin antibody; one with
type 2 cryoglobulinemia; and one with sarcoidosis. Of
note, the one individual with HIV infection was a Cau-
casian male whose biopsy did not reveal evidence of
HIV nephropathy (i.e., collapsing FSGS, tubular micro-
cysts, or endothelial tubuloreticular inclusions). One sub-
ject had lymphoma treated with chemotherapy 9 years
prior and was undergoing treatment with corticosteroids
for Waldenstrom’s macroglobulinemia at the time of re-
nal biopsy. Detailed clinical information regarding recent
nonsteroidal anti-inflammatory drug use was not avail-
able in most cases, but in no instance was there a strong
suspicion of drug-related glomerular disease at the time
of renal biopsy.
Pathologic findings
The renal biopsy findings in GTL are presented in
Table 2. By LM, the total number of glomeruli exam-
ined in each biopsy ranged from 6 to 100 (mean 25.1, me-
dian 20) and the percentage of globally sclerotic glomeruli
ranged from 0% to 45% (mean 7%, median 1.8%). The
percentage of segmental lesions per biopsy ranged from
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Table 2. Summary of pathologic findings in glomerular tip lesion (GTL)
Morphology of
Global segmental lesions
glomerular Segmental glomerular mean % Tubular
sclerosis lesions by location segmental lesions atrophy/
mean % mean % glomeruli per case per case interstitial
Distribution of Number glomeruli fibrosis scorea
segmental lesions (% cases) per case GTL Peripheral Indeterminate Cellular Sclerosing mean
All GTL cases 47 (100) 7 12 3 5 81 19 0.7
GTL only 12 (26) 9 15 0 0 81 19 0.6
GTL + peripheral 3 (6) 11 9 7 0 100 0 0.7
GTL + indeterminate 17 (36) 8 10 0 7 73 27 0.8
GTL + peripheral + indeterminate 15 (32) 3 10 7 9 85 15 0.5
aScores range 0 to 3+.
1.7% to 41.7% (mean 19.0%, median 16.8% of glomeruli
per biopsy). By definition, all 47 GTL biopsies contained
at least one GTL (mean 11.9%, median 9% of glomeruli
per biopsy, range 1.6% to 30%). Twelve biopsies (25.5%)
contained exclusively GTL lesions (Fig. 1A to C); three
biopsies (6.4%) showed GTL plus peripheral (non-GTL)
segmental lesions (Fig. 1D); 17 biopsies (36.2%) demon-
strated GTL plus segmental lesions of indeterminate lo-
cation (Fig. 1E); and 15 biopsies (31.9%) included GTL
plus peripheral and indeterminate lesions. Of note, no
initial biopsy demonstrated segmental lesions in the per-
ihilar region.
Most segmental glomerular lesions in the cohort of
GTL were cellular (average 81% of lesions per biopsy)
and a minority was sclerosing (average 19% of lesions
per biopsy) (Table 2). Among the entire cohort of 47 GTL
biopsies, 33 (70.2%) had cellular lesions only, five (10.6%)
had sclerosing lesions only, and nine (19.1%) had both
cellular and sclerosing lesions. Of the 12 biopsies show-
ing exclusively GTL, nine (75%) had cellular lesions only,
two (16.7%) had sclerosing lesions only, and one case
(8.3%) showed both cellular and sclerosing lesions. On
average, 81% of glomerular lesions in this group were cel-
lular and 19% were sclerosing (Table 2). All three biop-
sies with GTL and peripheral lesions showed only cellular
lesions. Of the 17 biopsies with both GTL and indetermi-
nate lesions, 12 (70.6%) had cellular lesions only, three
(17.6%) had sclerosing lesions only, and two (11.8%) had
both cellular and sclerosing lesions. On average, 73% of
segmental lesions per biopsy in this group were cellular
and 27% were sclerosing. Of the 15 biopsies with GTL,
peripheral and indeterminate lesions, 11 (73%) had cel-
lular lesions only, one (7%) had sclerosing lesions only,
and three (20%) showed both cellular and sclerosing le-
sions. On average, 85% of segmental lesions in this group
were cellular and 15% were sclerosing. Twenty-two biop-
sies showed mild focal mesangial hypercellularity (mean
score 0.5; scale 0 to 3+) and no biopsy demonstrated dif-
fuse mesangial hypercellularity.
Most GTL biopsies showed either no or mild intersti-
tial fibrosis and tubular atrophy (mean score 0.7+; scale
0 to 3+). Fourteen biopsies had patchy interstitial edema
and a mild interstitial mononuclear inflammatory cell
infiltrate, without significant interstitial fibrosis. Acute
tubular injury was identified in 14 biopsies (mean score
1.9+, range 1 to 3+). Proximal tubular epithelial cells
frequently contained focal intracytoplasmic protein re-
sorption droplets. Arteriosclerosis was generally mild
(mean score 0.7+; scale 0 to 3+).
IF demonstrated focal and segmental glomerular stain-
ing for IgM (in 77.7% of biopsies) and for C3 (in 43.2%
of biopsies). The mean intensity (MI) of staining for IgM
was 0.8 ± 0.1 (scale 0 to 3+) and, for C3, 0.6 ± 0.1.
No biopsy showed diffuse mesangial IgM staining, or the
predominant C1 staining characteristic of C1q nephropa-
thy (MI for C1q 0.14 ± 0.05). No biopsy had glomerular
staining for IgG or IgA. EM demonstrated extensive foot
process effacement (mean 93.5%, range 50% to 100%)
(Fig. 2A). There was no evidence of underlying structural
glomerular basement membrane abnormalities, immune-
type electron-dense deposits or endothelial tubuloretic-
ular inclusions, including the one patient with HIV
infection. The tip lesions often displayed endocapil-
lary foam cells and swelling of the overlying podocytes
(Fig. 2B).
Clinical follow-up
Follow-up renal data were obtained in 29 patients and
the mean follow-up period was 21.6 months (range 3 to
96 months) (Table 3). There were no statistically signifi-
cant differences in presenting clinical features or biopsy
findings between those patients with vs. without follow-
up. All 29 patients received immunosuppressive therapy,
including steroids in 28. Seven of these patients had se-
quential treatment with steroids followed by another im-
munosuppressive agent, including cyclosporine (CSA)
alone (N = 3), CSA + intravenous cytoxan (N = 2),
or intravenous cytoxan alone (N = 2). One patient
was treated with CSA alone. Twenty-two patients, all
of whom received steroids, also received an angiotensin-
converting enzyme (ACE) inhibitor or angiotensin II re-
ceptor blocker (ARB).
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Fig. 2. A representative example of a
glomerulus with glomerular tip lesion
(GTL). (A) This example shows severe
effacement of foot processes overlying patent
capillaries. There are no electron dense
deposits or glomerular basement membrane
abnormalities (electron micrograph × 2000).
(B) Ultrastructurally, the tip lesions display
endocapillary foam cells and marked swelling
of the overlying podocytes, with effacement
of foot processes (electron micrograph
×2000).
Seventeen patients (58.6%) achieved complete remis-
sion defined as trace or no proteinuria (<300 mg/day)
and normal renal function at last follow-up (mean 15.5
months, range 3 to 30 months). All 17 patients with com-
plete remission had received steroid therapy, including 13
treated with prednisone alone; three who also received
CSA; and one who also received IV cytoxan followed
by CSA. Thirteen of the 17 patients also received an
ACE or ARB. The mean initial serum creatinine in com-
plete remission patients was 1.15 mg/dL (range 0.5 to
2.7 mg/dL) and the mean final serum creatinine was 1.05
mg/dL (range 0.7 to 2.5mg/dL). The mean 24-hour urinary
protein excretion decreased from 7.8 ± 1.05g (initial) to
negative/dipstick trace at last follow-up.
Four patients (13.8%) had partial remission defined
as nonnephrotic proteinuria (<2 g/day) and stable renal
function at last follow-up (at 3, 13, 18, and 48 months, re-
spectively). All four partial remission patients received
steroids + ACE or ARB. One patient underwent com-
plete remission following 6 months of steroid therapy
but nephrotic syndrome relapsed 6 months later and was
partially controlled with CSA at last follow-up. One par-
tial remission subject, treated with steroids + ACE, had
persistent 2+ dipstick protein when he suffered an un-
natural death 3 months after initial presentation. One
partial remission patient with steroid-resistant nephrotic
syndrome showed marked diminution of proteinuria (to
1 g/24 hours) with CSA + ACE/ARB; 3 years later,
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Table 3. Comparison of treatment and final remission status with pattern of segmental lesions in glomerular tip lesion (GTL)
GTL + GTL+ GTL + peripheral +
All GTL GTL alone GTL + othera peripheral indeterminate indeterminate
Follow-up available number 29 9 20 1 10 9
Mean follow-up months (range) 21.6 (3–96) 28.0 (4–90) 16.4 (1–96) 3b 12.7 (3–25) 27.6 (5–96)
Therapy
Steroids only 21 7 14 1 6 7
Steroids + otherc 7 2 5 0 3 2
Cyclosporine only 1 0 1 0 1 0
ACE/ARBd 22 7 15 1 7 7
Outcome
Complete remission 17 6 11 0 8 3
Partial remission 4 1 3 1 1 1
No remission 8 2 6 0 1 5
ACE/ARB is angiotensin-converting enzyme/angiotensin receptor blocker.
aGTL and peripheral and/or indeterminate; bFollow-up for one patient only; cSteroids + other immunosuppressive agent (cyclosporine or cytoxan); dAll patients
who received ACE/ARB also received steroids.
nephrotic syndrome relapsed and was partially controlled
(1 g/24 hours) with cytoxan + ACE + ARB at last
follow-up. In one partial remission individual, steroid
therapy was discontinued after 3 months because of un-
controlled hyperglycemia; this patient had persistent, al-
beit markedly reduced proteinuria (from 12 to 1 g/day)
on ACE alone 18 months later. The mean initial serum
creatinine in partial remission patients was 1.15 mg/dL
(range 0.6 to 1.6 mg/dL) and the mean final serum crea-
tinine was 1.18 mg/dL (range 1 to 1.4 mg/dL). The mean
initial 24-hour urinary protein excretion in partial remis-
sion patients was 10.4 ± 3.17 g and the mean final 24-hour
urinary protein excretion was 1.0 ± 0.0 g.
Eight patients (27.6%) were classified as nonremitters
because of persistent and significant proteinuria (dip-
stick 2+ or >2 g/day) at last follow-up (mean 27.9 ±
11.9 months, range 4 to 96 months). Treatment regi-
mens in these eight subjects consisted of: prednisone
alone (one patient); prednisone + ACE/ARB (three pa-
tients); prednisone + CSA + ACE/ARB (one patient);
prednisone + cytoxan (one patient); prednisone + cy-
toxan + ACE/ARB (one patient); and CSA + ACE/ARB
(one patient). Steroid therapy was avoided in one pa-
tient because of morbid obesity, and poor compliance
with medication was suspected in one other patient. Of
note, three of these patients, all of whom received steroids
+ ACE/ARB, demonstrated marked reductions in pro-
teinuria at last follow-up (from 19.8 to 4.9 g, from 12.5 to
6 g, and from 12 to 3 g, respectively) but did not fulfill the
criteria for remission of nephrotic syndrome. The mean
initial 24-hour urinary protein excretion in nonremitting
patients was 11.7 ± 1.91 g and the mean final 24-hour uri-
nary protein excretion was 6.82 ± 1.57 g. The mean initial
serum creatinine in the eight nonremitting patients was
1.3 mg/dL (range 0.8 to 2.2 mg/dL). At last follow-up, five
nonremitting patients had a mean serum creatinine of 1.3
mg/dL (range 0.9 to 2.1 mg/dL) and one had a creatinine
clearance of 78 mL/min. Renal functional data were un-
available for one individual. The single patient treated
with steroids alone progressed to ESRD after 36 months’
follow-up.
Of the 16 patients who had renal insufficiency at pre-
sentation, three had normal renal function at last follow-
up (mean initial serum creatinine 1.6 ± 0.21 mg/dL, mean
final serum creatinine 0.9 ± 0.1 mg/dL), eight were lost to
follow-up, and the remaining five had persistent but sta-
ble renal impairment (mean initial serum creatinine 2.0 ±
0.22 mg/dL, mean final serum creatinine 1.8 ± 0.3 mg/
dL).
Relapse of nephrotic syndrome after initial response
to immunosuppressive therapy was documented in two
patients (at 6 months post-therapy and 43 months post-
therapy, respectively); both patients were classified as
partial remitters at last follow-up. Of the 18 patients
for whom follow-up renal data were not obtained, one
patient died of sepsis while receiving steroids 1 month
postrenal biopsy; one, who had received steroids, died of
a myocardial infarction 6 months postrenal biopsy; three
patients had follow-up of less than 2 months; and 13 were
lost to follow-up.
Repeat renal biopsies in GTL
Three GTL patients underwent repeat renal biopsy
because of failure to remit following steroid therapy,
including the single patient who progressed to ESRD.
This patient was a 29-year-old woman who presented
with nephrotic syndrome and normal renal function. Ini-
tial renal biopsy demonstrated cellular segmental lesions
in 8/22 glomeruli (36.4%), including five cellular GTL,
one cellular peripheral lesion, and two cellular indeter-
minate lesions (Fig. 1F and G). There was no evidence
of segmental sclerosing lesions, global glomerulosclero-
sis, interstitial fibrosis, tubular atrophy, or arteriosclerosis.
She underwent repeat renal biopsy 3 years later because
of steroid-resistant nephrotic syndrome and progressive
renal failure. The second biopsy showed global glomeru-
losclerosis affecting four of eight glomeruli (50%) and
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Table 4. Summary of clinical-pathologic correlations in glomerular tip lesion (GTL)
Initial
Initial 24-hour Final
24-hour urine 24-hour Initial
urine protein urine Initial Glomerular serum Final
protein excretion protein serum filtration creatinine > serum No
excretion > 3 g/day excretion creatinine ratea 1.2 mg/dL creatinine remission
Age NS NS NS NS NS 0.007 NS NS
Male gender NS NS NS NS NS 0.002 NS NS
Initial 24-hour urine protein excretion — — NS NS NS NS NS 0.030b
Final 24-hour urine protein excretion NS NS — NS NS NS NS —
Initial serum creatinine NS NS NS — — — NS NS
Final serum creatinine NS NS NS NS NS 0.012 — 0.005b
Hypertension NS NS NS NS NS NS NS NS
% Global glomerulosclerosis NS NS NS NS 0.03c (−0.321) NS NS NS
% Segmental lesions NS 0.019 NS NS NS NS NS NS
% GTL NS 0.035 NS NS NS NS NS NS
% Peripheral lesions NS NS 0.02 0.037 0.032c (−0.306) 0.014 NS 0.020b
% Cellular lesions NS 0.025 NS NS NS NS NS NS
% Sclerosing lesions NS NS NS NS NS NS NS NS
Interstitial fibrosis/tubular atrophy NS NS NS NS NS NS NS NS
Interstitial edema 0.029 0.034 NS NS NS NS NS NS
NS is not significant; all correlations are positive.
aSee Methods section for details; bJonckheere-Terpstra test, nonremitters versus (complete remitters + partial remitters); cP value (Spearmann R value) for non-
parametric univariate linear regression analyses; results of multivariate analyses are in Results section. All results are P values, except GFR.
segmental sclerosis and hyalinosis in two glomeruli
(25%). The segmental lesions involved most of the
glomerular tuft, including the hilar pole, and were accom-
panied by severe interstitial fibrosis and tubular atrophy
and moderate arteriosclerosis (Fig. 1H).
A second patient showed segmental lesions in 3/19
glomeruli (15.6%) in the first biopsy, (including one cellu-
lar GTL, one cellular peripheral lesion, and one cellular
indeterminate lesion) without features of global glomeru-
losclerosis, interstitial fibrosis and tubular atrophy, or ar-
teriosclerosis. This patient’s second biopsy (performed 30
months later because of failure to respond to immuno-
suppressive therapy) showed global glomerulosclerosis
in 5/27 glomeruli (18.5%) and segmental sclerosing le-
sions in 3/27 glomeruli (11.1%), including one scleros-
ing GTL and two sclerosing lesions of indeterminate
location. These findings were accompanied by severe in-
terstitial fibrosis and tubular atrophy and moderate ar-
teriosclerosis. This patient had persistent NRP at last
follow-up.
A third individual showed mild global glomeruloscle-
rosis (1/6 glomeruli, 16.7%) and cellular GTL (1/6
glomeruli, 16.7%) in the first biopsy, accompanied by mild
arteriosclerosis. A repeat biopsy performed 2 months
later because of nonresponse to steroid therapy con-
tained five glomeruli, three of which showed segmental
lesions including one cellular GTL, one cellular periph-
eral lesion, and one segmental sclerosing lesion of inde-
terminate location. At last follow-up (19 months), this
patient was in complete remission and had normal renal
function.
Clinical-pathologic correlations in GTL
Correlations between pathologic and clinical findings,
including renal status at last follow-up, are summarized
in Table 4. Renal insufficiency at presentation correlated
with older age (P = 0.007), male gender (P = 0.002),
percentage of peripheral lesions (P = 0.014), and higher
final serum creatinine (P = 0.012), but not with duration
of symptoms prior to biopsy (data not shown). Five of
the 16 patients presenting with renal insufficiency showed
prominent diffuse acute tubular injury (mean score 2.4+,
range 2 to 3+); two of these patients had normal renal
function at last follow-up, similar to previously described
findings in MCD patients presenting with reversible acute
renal failure [17]. The other 11 cases showed mild or mod-
erate acute tubular injury (mean score 1.4, range 1 to 2).
Of note, the eight nonremitters presented with signifi-
cantly higher initial urinary protein excretion compared
to the 21 patients who had either partial (N = 4) or com-
plete remission (N = 17) (P = 0.030).
The degree of proteinuria correlated with intersti-
tial inflammation score (P = 0.045) and with interstitial
edema score (P = 0.029). In univariate analyses, the ex-
tent of tubular atrophy and interstitial fibrosis correlated
with % global glomerulosclerosis (P = 0.001), % scle-
rosing GTL (P < 0.001), and % segmental sclerosing
lesions (all locations) (P < 0.001). Nonparametric uni-
variate analyses showed that the estimated GFR at pre-
sentation correlated with: % global glomerulosclerosis
(R = −.0.321, P = 0.030); % peripheral lesions (scle-
rosing) (R = −0.317, P = 0.032); and % peripheral le-
sions (cellular + sclerosing) (R = −0.306, P = 0.032). By
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Table 5. Correlation of clinical findings with pattern of segmental lesions in glomerular tip lesion (GTL)
E
A B C D GTL + peripheral P
GTL only GTL + other GTL + peripheral GTL + indeterminate + indeterminate value
Number 12 35 3 17 15 NS
Age years 41.6 ± 6.2 49.5 ± 2.7 47.4 ± 5.8 49.5 ± 3.8 50 ± 4.6 NS
Gender male:female 7:5 18:17 2:1 7:10 10:5 NS
24-hour urinary protein
Initial g/day >3 g/day 7.6 ± 1.4 8.4 ± 0.7 5.8 ± 0.8 7.7 ± 0.9 9.9 ± 1.3 NS
number 10/11 30/32 3/3 14/15 13/14 NS
Last g/day 1.2 ± 0.7 3.5 ± 1.2a 3.0 ± 1.2b 1.7 ± 1.4 3.3 ± 1.4c
Edema number 11/12 33/34 3/3 17/17 13/14 NS
Albumin g/dL 2.3 ± 0.2 2.2 ± 0.1 2.4 ± 0.4 2.3 ± 0.2 2.1 ± 0.2 NS
Mean serum creatinine mg/dL
Initial 1.3 ± 0.2 1.4 ± 0.2 1.7 ± 0.1 1.1 ± 0.1 1.8 ± 0.3 NS
Last 1.1 ± 0.2 2.3 ± 0.8 2.3 ± 0.8 1.0 ± 0.1 1.6 ± 0.4 NS
Complete remission 6/9 11/20 0/1 8/10 3/9 NS
Hypertension N 6/12 22/34 3/3 13/15 6/14 NS
NS is not significant. All values are means ± standard error of the mean, except where otherwise stated.
a0.045 (B versus A); b0.028 (C v A); c0.027 (E versus A).
Table 6. Comparison of glomerular tip lesion (GTL), minimal change disease (MCD), and idiopathic focal segmental glomerulosclerosis (FSGS)
GTL (N = 47) MCD (N = 61) Idiopathic FSGS (N = 50) P value
Mean age years 47.5 ± 2.6 47.5 ± 2.3 32.6 ± 2.5a <0.001
Gender male:female 25:22 30:31 25:25 NS
Race/ethnicity number (%)
Caucasian 36 (76.6) 36 (59) 26 (52) NS
African American 6 (12.8) 10 (16) 11 (22) NS
Hispanic 4 (8.5) 3 (5) 11 (22) NS
Asian/other/unknown 1 (2.1) 12 (20) 2 (4) NS
Hypertension number (%) 28 (59) 15 (37.5)b 28 (56) <0.05
Creatinine mg/dL (range) 1.37 (0.5–5.2) 1.8 (0.6–17.2) 1.9 (0.4–14) NS
Nephrotic parameters
24-hour urinary protein excretion g/day 8.31 ± 0.63 9.56 ± 0.97c 6.9 ± 0.81c <0.05
Albumin g/dL (range) 2.27 (1.3–3.8) 2.06 (1–4.2) 2.9 (1.0–4.5) NS
Cholesterol mg/dL (range) 340.6 (132–778) 376.8 (168–904) 335 (156–873) NS
Edema number (%) 44 (93.6) 50 (98) 34 (68) NS
Nephrotic syndrome number (%) 41 (89.1) 59 (96.7) 27 (54)d <0.001
Mean duration of symptoms months 2.4 ± 0.4 1.8 ± 0.3e 48.6d <0.001
Data are mean ± SEM, except where otherwise indicated.
aP < 0.001, idiopathic FSGS versus GTL and versus MCD; bP < 0.05, MCD versus GTL and versus idiopathic FSGS; cP < 0.05 MCD versus idiopathic FSGS; dP <
0.001, idiopathic FSGS versus GTL and versus MCD; eIn MCD, “new onset” assumed at 1 month for purposes of analysis.
multiple (multivariate) linear regression analysis, only %
global glomerulosclerosis (P = 0.006) and % peripheral
lesions (P = 0.021) correlated with estimated GFR at pre-
sentation (combined Spearmann R value 0.471, overall
P = 0.005).
There was no significant difference in final remission
status (complete remisson versus partial remission ver-
sus no remission) when cases with GTL alone (N = 12)
were compared to cases of GTL with lesions at other
glomerular locations (N = 35) (P = 0.8795, Kruskal Wal-
lis test). However, compared to patients with GTL alone,
patients with GTL + any other lesion (peripheral and/or
indeterminate) had significantly higher final urinary pro-
tein excretion (P = 0.045) (Table 5). The percentage of
peripheral lesions (non-GTL) correlated significantly
with higher initial serum creatinine (P = 0.037), estimated
GFR at presentation (P = 0.032), renal insufficiency at
presentation (P = 0.014), and the absence of remission at
last follow-up (P = 0.020) (Table 4). No significant cor-
relations were identified between final remission status
and % GTL, % indeterminate lesions, % sclerosing le-
sions, interstitial fibrosis/tubular atrophy score, mesangial
proliferation score, or arteriosclerosis score. The devel-
opment of ESRD in only one GTL patient precluded the
identification of clinical or pathologic features that might
predict progression.
Comparison of GTL to MCD and idiopathic FSGS
As shown in Table 6, gender and racial/ethnic distri-
bution did not differ significantly between patients with
GTL, MCD, and idiopathic FSGS. However, GTL and
MCD patients were significantly older than patients with
idiopathic FSGS (P < 0.001). Although the clinical pre-
senting features of GTL demonstrated considerable over-
lap with those of MCD and idiopathic FSGS, the greatest
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similarity with respect to nephrotic parameters was found
between the GTL and MCD groups. In GTL and MCD,
89.1% and 96.7% of patients respectively presented with
full nephrotic syndrome compared to only 54% of pa-
tients with idiopathic FSGS (P < 0.001). Notably, both
GTL and MCD patients tended to present with abrupt
onset of nephrotic syndrome, as reflected by the signifi-
cantly shorter intervals from onset of symptoms to biopsy
compared to idiopathic FSGS (P < 0.001). The incidence
of hypertension at presentation was similar in GTL (59%)
and idiopathic FSGS (56%), and significantly higher than
in MCD (37.5%) (MCD vs. GTL and idiopathic FSGS,
each P < 0.05). There was no statistically significant dif-
ference in serum creatinine between the three groups,
reflecting the well-recognized occurrence of acute re-
nal failure in a subset of adults with MCD. Idiopathic
FSGS biopsies showed significantly more severe (2+ or
greater) tubular atrophy, interstitial fibrosis, and intersti-
tial inflammation (P < 0.0054). The extent of foot process
effacement in GTL cases (mean 93.5% of glomerular
capillary surface area) was more similar to that of MCD
(mean 91.6%) than idiopathic FSGS (mean 75%).
DISCUSSION
Pure GTL has been reported in 4.9% to 13.5% of FSGS
biopsy series [1, 4, 5]. In the first description of 20 pa-
tients with GTL, this lesion comprised 13.5% of biop-
sies initially classified as FSGS [1]. GTL also may coexist
with other lesions of FSGS, in either perihilar, peripheral,
or indeterminate locations. In a study of 44 nephrotic
children with FSGS, including 33 with repeat biopsies
or autopsies, Morita et al [5] classified the locations of
segmental lesions as either GTL (“paratubular”), periph-
eral, hilar (i.e., perihilar), or indeterminate. GTL was
found in 23 initial biopsies (52.3%) but 19 of these cases
(82.6%) showed hilar sclerosis in either the initial or re-
peat biopsies, similar to idiopathic FSGS. Only four cases
(9.1%) were classified as pure GTL, based on the absence
of hilar or indeterminate sclerosing lesions in the initial
or repeat biopsies, or at autopsy [5]. Similarly, Schwartz
et al [4] described GTL in 26% of 81 FSGS biopsies but
tip lesion was the sole finding in only four cases (4.9%).
In neither of these studies was there a statistically signif-
icant difference in outcome for the peripheral or GTL
groups compared to the hilar sclerosis patients, perhaps
reflecting the small number of pure peripheral or GTL
cases examined. We did not identify perihilar sclerosis
in any of our 47 initial biopsies of GTL, supporting that
GTL is morphologically distinct. However, the develop-
ment of perihilar sclerosis on repeat biopsy in one of our
cases indicates that rare cases may evolve into a pattern
of idiopathic FSGS not otherwise specified [12].
Howie and Brewer [1] have demonstrated that the fre-
quency of GTL lesions is directly related to the number
of tissue sections examined, with most glomeruli involved
when 100 sections were examined, whereas the fraction
of glomeruli with GTL in each biopsy ranged from 3%
to 16% when only one-tenth of available sections were
studied. However, given the random orientation of the
spherical glomerulus within the tissue block, it follows
that some GTL may not always be visualized, even after
exhaustive sectioning. Precise determination of the fre-
quency of GTL properly requires the use of stereologic
methodologies that are not practicable in routine renal
biopsy practice, and, moreover, cannot be applied ret-
rospectively in a clinical-pathologic study of the present
kind. Of note, using conventional histologic techniques,
Haas and Yousefzadeh [18] identified GTL in five of
eight (62.5%) pediatric autopsy specimens with “lipoid
nephrosis” from the archives of Johns Hopkins Hospital,
but only 0.3% to 4.4% of glomeruli had GTL, despite
examination of 410 to 1168 glomeruli per case. Similarly,
using standard biopsy examination techniques, we found
that GTL is always a focal histologic finding, with no case
demonstrating >50% glomerular involvement.
Howie [3] proposed a classification of segmental
glomerular lesions based on the extent of glomerular in-
volvement in addition to the location of individual le-
sions within the glomerular tuft. In that study, cases with
GTL involving all or nearly all glomeruli that otherwise
resembled MCD (i.e., did not show mesangial prolifera-
tion or sclerosing lesions at other sites) had a uniformly
benign course with complete remission occurring in all
10 cases. Cases of diffuse GTL with mesangial hypercel-
lularity, cases with diffuse multiple segmental lesions at
various parts of the glomerular tuft involving all or nearly
all glomeruli, and cases with focal GTL (i.e., fewer than
50% of glomeruli affected) behaved more like idiopathic
FSGS, with failure to enter remission in many cases [3].
Our findings, on the other hand, indicate that focal le-
sions are the rule in cases of GTL when renal biopsies
are examined by conventional techniques. None of our
cases showed diffuse mesangial hypercellularity, and the
presence of mild segmental mesangial hypercellularity in
a minority of cases did not have any significant impact
on clinical presenting features, response to therapy, or
long-term renal outcome. Importantly, perihilar segmen-
tal lesions were not identified in any initial biopsy in this
series; only one case that progressed to ESRD showed hi-
lar lesions on repeat biopsy. Thus, while perihilar lesions
were not an exclusion criterion for case selection, the dis-
covery that they were absent in all initial GTL biopsies
provides post hoc evidence to support a classification sys-
tem that requires exclusion of any perihilar sclerosis in its
definition of GTL [12].
In this study, we demonstrate that GTL frequently co-
exists with other lesions whose relationship to the prox-
imal tubule is uncertain (peripheral and/or indetermi-
nate). This raises the important question of whether GTL
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cases with peripheral and/or indeterminate segmental le-
sions are distinct from cases with GTL alone and should
be classified separately as FSGS not otherwise speci-
fied. The presence of peripheral lesions correlated with
renal insufficiency at presentation, higher final urinary
protein and absence of complete remission at last follow-
up. Thus, cases that showed peripheral lesions (GTL +
peripheral, or GTL + peripheral + indeterminate) had
significantly worse renal outcomes compared to cases of
GTL alone or GTL + indeterminate. On the other hand,
when we dichotomized cases of GTL alone versus cases
of GTL + any other lesion, there was no difference in
final remission status between the two groups, which sup-
ports the concept that these subgroups constitute a sin-
gle clinical-pathologic entity. In reviewing all GTL cases,
we frequently encountered apparently peripheral and/or
indeterminate segmental lesions that could be classified
as GTL when tracked through adjacent tissue sections.
Thus, we cannot exclude the possibility some peripheral
and/or indeterminate lesions are GTL whose relationship
to the tubular pole is not visualized in the sections exam-
ined or that evolved beyond the tip domain. Given the
constraints of routine tissue processing, and the inability
to precisely distinguish GTL, peripheral, and indetermi-
nate lesions without resort to exhaustive tissue sectioning,
we believe it is justifiable to include cases of GTL with
peripheral and/or indeterminate lesions within the diag-
nostic category of GTL, while noting that the presence
of peripheral lesions in GTL may portend a worse clini-
cal outcome, more akin to idiopathic FSGS not otherwise
specified.
The prognostic import of sclerosing versus cellular
GTL has not been examined before. Most of the focal
lesions in this study were cellular in type. The findings of
sclerosing GTL in repeat biopsies from three individuals
whose initial biopsies all showed only cellular lesions is
consistent with the hypothesis advanced by Howie and
Brewer [1] that cellular GTL may evolve into scleros-
ing GTL. Of note, one of these three patients progressed
to ESRD, one had persistent nephrotic proteinuria, and
one subsequently entered complete remission. However,
the % segmental sclerosing lesions in the initial biopsy
did not correlate with estimated GFR at presentation, or
with follow-up renal functional data, suggesting that the
presence of sclerosing versus cellular segmental lesions
in GTL does not carry major prognostic import.
In the initial study of Howie and Brewer of GTL [1], all
sixteen patients who were treated with steroids showed
decreased proteinuria and only one untreated patient
developed progressive renal impairment, suggesting a
favorable prognosis. Hogan-Moulton et al described a
similar high rate of steroid responsiveness in GTL, with
progression to ESRD occurring in only 1 of 28 patients
[abstract A418; Hogan-Moulton AE et al, J Am Soc
Nephrol 8:87A, 1997]. Beaman et al [20] reported remis-
sion of nephrotic proteinuria in 10 of 18 patients with
GTL following steroid treatment, and partial remission
of proteinuria in seven. Similarly, Ito et al [21] reported
significantly better clinical outcomes in children with id-
iopathic nephrotic syndrome whose biopsies showed pe-
ripheral segmental lesions compared to perihilar lesions.
Although not described in detail, it is probable that at
least some of the peripheral lesions in that study included
cases of GTL. In the studies of Schwartz et al [4] and
Morita et al [5], three of four patients with initial biopsy
findings of pure GTL had complete remission and sta-
ble renal function, and one had normal renal function
and minimal proteinuria following steroid therapy. Other
groups, on the other hand, reported no prognostic sig-
nificance for “tip changes” [4, 5] or peripheral lesions
[22, 23] compared to idiopathic FSGS. Whether this dis-
crepancy reflects the possible inclusion of other primary
glomerular diseases beside GTL [24–26] or the small
number of GTL cases in some series [4, 5] is uncertain.
Our study, which is the largest single-center series of GTL
yet reported, confirms the high likelihood of response to
immunosuppressive therapy in GTL, with complete or
partial remissions occurring in 72.4% of patients.
Our data strongly support the hypothesis that GTL
falls within the MCD/FSGS disease spectrum. The high
incidence of full nephrotic syndrome and abrupt clinical
onset seen in GTL resemble the presentation of MCD.
The remission rate of 72.4% of GTL (58.6% complete
and 13.8% partial) is intermediate between published
remission rates for adult onset MCD (complete or par-
tial 81% to 91%, complete 72.5% to 77.3%) [27, 28] and
idiopathic FSGS with nephrotic syndrome (complete or
partial, 50% to 65.7%, complete remission, 20% to 41%)
[22, 23, 29, 30]. The low incidence of documented relapse
in our series (2/29 patients) may reflect the relatively short
follow-up (median 13 months, range 3 to 96 months). By
comparison, a recent study reported relapse of nephrotic
syndrome in 33% of adult MCD patients, with a median
time to relapse of 30 months [31]. ESRD is a rare oc-
currence in GTL, affecting only one of 29 patients in the
present study. This extremely low incidence is compara-
ble to previously reported incidences of ESRD in MCD;
Nolasco et al [27] reported death from uremia in only
one of 89 adults with MCD, whereas Korbet, Schwartz,
and Lewis [28] described progression to ESRD in two of
40 adult patients with MCD. By contrast, the reported
incidence of ESRD in idiopathic FSGS with nephrotic
syndrome is 50% over 5 to 10 years [19]. Thus, outcome
in GTL appears better than that of idiopathic FSGS with
respect to both achievement of complete remission and
renal functional preservation, at least within the relatively
short period of follow-up in this study. Among the eight
GTL patients who had renal insufficiency at presenta-
tion and for whom follow-up data were available, five
subsequently had stable renal function, and three had
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normal renal function. These findings support a role for
heavy proteinuria precipitating reversible acute tubular
injury in some GTL patients, as reported for patients with
MCD [17].
These similarities to MCD and FSGS raise ques-
tions about how GTL should be classified within the
MCD/FSGS spectrum. Is GTL a nonspecific morpho-
logic feature seen in some patients with MCD or should
it be considered a morphologic variant of FSGS? Our
data support that GTL occupies an intermediate position
within the clinical-pathologic spectrum of MCD/FSFS
and there is some validity to both approaches. From
a practical diagnostic standpoint, GTL may be consid-
ered a highly favorable prognostic subcategory within the
broader clinical-pathologic continuum of MCD/FSGS.
Although the presence of perihilar sclerosis was not an
exclusion criterion for diagnosis of GTL in this study,
the absence of this finding in all initial GTL biopsies val-
idates the recognition of GTL as a phenotypically dis-
tinct variant whose segmental lesions are paratubular and
predominantly cellular in character. The favorable out-
come with respect to steroid responsivity and extremely
low incidence of progression to ESRD indicate that this
distinction is clinically relevant. Future studies of out-
come in idiopathic nephrotic syndrome should control
for patients with this favorable morphologic variant. Ad-
ditional studies are needed to determine the morphogen-
esis and potential reversibility of this lesion.
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